abstract
Author information
- Winthrop-University Hospital, Mineola, NY.
INTRODUCTION:
To assess impact of outpatient intraperitoneal (IP) chemotherapy on quality of life (QOL).
METHODS:
Cross
sectional study of patients with optimally cytoreduced stage III and IV
ovarian cancer who received IP chemotherapy between 2006 and 2011 at a
single institution. A self administered, anonymous survey assessed 4
domains: physical health (PH), mental health (MH), social health (SH)
and patient subjective sense of worth (WO) of IP chemotherapy.
RESULTS:
Seventy-one
participants were mailed surveys. 52 (73.2%) returned the survey, 4
were excluded (incomplete) and 48 (67.6%) were included in the final
sample. Mean age was 62.4 (±10.3). Mean time from completion of
chemotherapy was 30.8 months. In the PH domain, 50.0% reported that
fatigue severely affected QOL. Other aspects were pain (39.6%), GI
problems (37.5%) and "chemotherapy brain" (29.2%). In the MH domain, 25%
reported significant stress and 20.8% experienced anxiety. In the SH
domain, 27.5% reported therapy interfered with work. The majority
(83.3%) reported the effectiveness of IP chemotherapy was "worth" the
side effects, 95.8% did not regret it, and 87.5% would recommend it to a
friend. Eleven patients had recurrent disease, of whom 90% indicated IP
chemotherapy was worthwhile and none regretted the decision to receive
this therapy.
CONCLUSION/IMPLICATIONS:
IP
chemotherapy has been shown to improve OS and PFS and yet is not
universally prescribed. It is known to have more toxicities compared to
IV chemotherapy. The present study suggests that while these side
effects affect QOL, patients feel that the therapy is worthwhile and do
not regret treatment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.